UNLABELLED: We evaluated the significance of the preoperative serum C-reactive protein (CRP) level as a prognostic indicator in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Two hundred and three patients who had undergone a curative resection of NSCLC were retrospectively reviewed. RESULTS: The proportion of the tumor size over 3 cm per patient in the CRP-positive group (> or =0.5 mg/dL: n=38) was significantly higher than that in the CRP-negative group (<0.5 mg/dL: n = 165). The proportion of the adenocarcinoma in CRP-positive group was significantly lower than that in CRP-negative group. The overall and disease specific survival rates in the CRP-positive group were significantly lower than the rates in the CRP-negative group. Based on a multivariate analysis, the preoperative serum CRP level was selected as one of the unfavorable indicators regarding survival. CONCLUSION: The preoperative serum CRP level is an independent and significant indicator predictive of a poor prognosis in patients with NSCLC.
UNLABELLED: We evaluated the significance of the preoperative serum C-reactive protein (CRP) level as a prognostic indicator in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Two hundred and three patients who had undergone a curative resection of NSCLC were retrospectively reviewed. RESULTS: The proportion of the tumor size over 3 cm per patient in the CRP-positive group (> or =0.5 mg/dL: n=38) was significantly higher than that in the CRP-negative group (<0.5 mg/dL: n = 165). The proportion of the adenocarcinoma in CRP-positive group was significantly lower than that in CRP-negative group. The overall and disease specific survival rates in the CRP-positive group were significantly lower than the rates in the CRP-negative group. Based on a multivariate analysis, the preoperative serum CRP level was selected as one of the unfavorable indicators regarding survival. CONCLUSION: The preoperative serum CRP level is an independent and significant indicator predictive of a poor prognosis in patients with NSCLC.
Authors: Xia Pu; Yuanqing Ye; Margaret R Spitz; Liang Wang; Jian Gu; Scott M Lippman; Michelle A T Hildebrandt; Waun Ki Hong; John D Minna; Jack A Roth; Ping Yang; Xifeng Wu Journal: Clin Cancer Res Date: 2012-09-13 Impact factor: 12.531
Authors: Adriana Villaseñor; Anita Ambs; Rachel Ballard-Barbash; Kathy B Baumgartner; Anne McTiernan; Cornelia M Ulrich; Marian L Neuhouser Journal: Breast Cancer Res Treat Date: 2011-04-01 Impact factor: 4.872
Authors: Marta Lukaszewicz-Zając; Barbara Mroczko; Mirosław Kozłowski; Jacek Nikliński; Jerzy Laudański; Maria Siewko; Maciej Szmitkowski Journal: J Clin Lab Anal Date: 2012-02 Impact factor: 2.352
Authors: Valéria Jósa; Marcin Krzystanek; Tamás Vass; Tamás Lang; Viktória Juhász; Kamilla Szilágyi; Balázs Tihanyi; László Harsányi; Zoltán Szállási; Ferenc Salamon; Zsolt Baranyai Journal: Pathol Oncol Res Date: 2015-03-13 Impact factor: 3.201